Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Mad2 who wrote (1820)	12/6/1999 2:46:00 PM
From: pz	Read Replies (1) \| Respond to of 5582

From Yahoo: 550K shares by: nursepoop (old/Vancouver, USA) 12/6/1999 2:03 pm EST Msg: 14754 of 14761 Talked with IR today. 1). Although registered (550 K shares) these share do not have to be exercised and may never be. They can add extensions with the SEC without ever exercising the warrants. 2) Machinery will be up to speed on new lines this week. 3) Back orders for Zicam will be filled, from a 4-week delay down to 2-week backorder. “Unless we get more orders to set us back again”. 4) They don't want or expect a share price to drop anymore that most of us. He was surprised that the price was returning to this low undervalued level. We talked about press releases and such . They may do a press release if investors feel it's needed to ensure investor confidence. Good news will be released but not before deals are completed On the gum contracts. Nurse

To: Mad2 who wrote (1820)	12/6/1999 3:20:00 PM
From: Eric Fader	Read Replies (1) \| Respond to of 5582

I beg to differ. A proclamation like that, based on technical analysis applied to a thinly traded stock, would not be reliable even if its source were not someone with an acknowledged bias. Whether GUMM closes below any particular "magic number" as a result of short-term selling or manipulation will neither influence nor foreshadow the stock's performance once the backlog of Zicam orders is cleared. My understanding is that, at such time, the advertising campaign would finally begin in full force (Mike, Dan, Bo or Howard - is that still believed to be correct?) and Zicam's journey toward "household name" status will accelerate, along with GUMM's stock price. Furthermore, the announcement of the results of the second clinical study will be a lightning bolt that will smite short-sellers without warning. That's all from me for today. This back-and-forth stuff is getting tedious. I still calmly and confidently expect a $30 stock price and a likely retail investor buying frenzy within a couple of months.